Navigation Links
Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time
Date:7/28/2011

perational leverage we expect to achieve for the full year will drive good earnings growth in 2011 and we reiterate our aspirational growth targets.

PLANNED PRODUCT LAUNCHES

Subject to obtaining the requisite regulatory/governmental approvals, planned product launches over the next 12 months include:

  • EQUASYM® for the treatment of ADHD in certain European countries;

  • RESOLOR® in certain European countries, for the symptomatic treatment of chronic constipation in women for whom laxatives fail to provide adequate relief;

  • DERMAGRAFT® for the treatment of Diabetic Foot Ulcers ("DFU") in Canada;

  • VPRIV for the treatment of Type 1 Gaucher disease in certain European and Latin American countries; and

  • FIRAZYR® for the symptomatic treatment of acute attacks of hereditary angioedema ("HAE") in the US and certain European and Latin American countries.

SECOND QUARTER 2011 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS


Products


FIRAZYR - for the treatment of HAE

  • On June 23, 2011 Shire announced that the Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration ("FDA") recommended, by a vote of twelve to one, that the efficacy and safety data for FIRAZYR provides substantial evidence to support approval of FIRAZYR for the treatment of acute attacks of HAE in patients 18 years and older. In addition, by a vote of eleven to one, with one abstention, the Committee recommended self-administration of the drug by patients. Shire has been assigned an action date of August 25, 2011 under the Prescription Drug User Fee Act.

<
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. Neogen Reports 27% Increase in Quarterly Net Income
2. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
3. Microbix Has Best-Ever Quarterly Sales
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
7. Quest Diagnostics Declares Quarterly Cash Dividend
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
10. Abbott Declares 343rd Consecutive Quarterly Dividend
11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 FLX Bio, Inc., a biopharmaceutical ... cancer immunotherapies, announced today that it has appointed ... and William Ho , M.D., Ph.D., as Chief ... management team led by veterans of Flexus Biosciences, Inc., ... Scientific Officer; Jay Powers , Ph.D., Vice President, ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... There’s ... Minerva is the first commercially available new FDA approved system in the ... Success rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ... With a focus on evidence-based research and clinical application, the event gathered industry ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... for venture capital funds, investment firms and animal health companies to hear from ... raised $160 million. Several have also received licensing agreements or distribution contracts. ...
Breaking Biology Technology:FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3
... 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced preliminary ... 30, 2007 and updated its financial,outlook for ... in conjunction with the,release of Boston Scientific ...
... 19 An affiliate of,Phlo Corporation (Pink ... distribution of its vitality product, AQUISS(TM), in ... within Northern California and has,been introduced into ... Springs area. In Northern California, AQUISS(TM) ...
... Radi Medical Systems Sponsors Case Review with Drs. Morton Kern, Nico ... ... Oct. 19 The use,of fractional flow reserve (FFR) for optimizing ... Cardiovascular,Therapeutics symposium, TCT 2007, which will take place Oct. 20-25 in,Washington. ...
Cached Biology Technology:Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 3Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 4Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 5Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 6Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 7Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 8Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 9Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 10Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 11AQUISS Continues Expansion Into New Territory 2Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007 2
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... cycle of ancient flatworms that cause schistosomiasis, Case Western ... to development of the parasites within humans a ... the activator, which turns on rapid growth, is in ... Schistosomiasis, which causes organ damage and failure, ...
... Fla. -- Invasive Burmese python hatchlings from the Florida ... to potentially expand their range through ocean and estuarine ... the Journal of Experimental Marine Biology and Ecology ... conducted by researchers from the U.S. Geological Survey, ...
... Daily doses of a soy germ-based nutritional ... significantly reducing hot flash frequency after 12 weeks ... women published in the peer-reviewed Journal of ... that S-equol, produced from the isoflavone daidzein during ...
Cached Biology News:Crucial gene activator in slow-killing parasite identified 2Crucial gene activator in slow-killing parasite identified 3Salt water alone unlikely to halt Burmese python invasion 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 3New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 4New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 5
...
MultiWash III w/ 12-portStandard Manifold...
... Streptavidin Sepharose High Performance, 5 ml. ... used in HiTrap Streptavidin columns for ... for packing into Tricorn 5/50 GL, ... larger scale purifications are required.Extremely useful ...
...
Biology Products: